NCT05510427 is a Phase 1 clinical trial of Infigratinib in Cholangiocarcinoma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT05510427?

NCT05510427 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT05510427?

Interventions in NCT05510427: Infigratinib, Atezolizumab, Bevacizumab.

What condition does NCT05510427 study?

NCT05510427 studies Cholangiocarcinoma, Liver Cancer.

Is NCT05510427 still recruiting?

NCT05510427 is currently withdrawn. Last updated 15 August 2023.

Last reviewed 2023-08-15 · How we verify

NCT05510427

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Withdrawn Phase 1 Last updated 15 August 2023

What this trial tests

Phase 1 trial testing Infigratinib in Cholangiocarcinoma. Withdrawn.

Timeline

7 August 2023

Primary endpoint
7 August 2023

7 August 2023

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Start date	7 August 2023
Primary completion	7 August 2023
Estimated completion	7 August 2023

Drugs / interventions tested

Infigratinib (INFIGRATINIB) — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Cholangiocarcinoma — all drugs for Cholangiocarcinoma →
Liver Cancer — all drugs for Liver Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Cholangiocarcinoma or Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To find the highest tolerable dose of infigratinib that can be given in combination with bevacizumab and atezolizumab to patients with advanced/metastatic CCA with a FGFR2 mutation.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment.
Ruan R, Li L, Li X, Huang C, et al · · 2023 · cited 86× · PMID 36966334 · DOI 10.1186/s12943-023-01761-7
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment.
Liu Y, Yang H, Li T, Zhang N. · · 2024 · cited 23× · PMID 39295859 · DOI 10.3389/fimmu.2024.1460282
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Yoo C, Hyung J, Chan SL. · · 2024 · cited 19× · PMID 38638168 · DOI 10.1159/000531458
Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents.
Nishida N, Kudo M. · · 2024 · cited 14× · PMID 38751556 · DOI 10.1159/000534443
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, et al · · 2023 · cited 14× · PMID 37213397 · DOI 10.3748/wjg.v29.i17.2571

Verify or expand the search:

Other trials of Infigratinib

Trials testing the same drug.

NCT07393373 — Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia · Phase 2 · enrolling by invitation
NCT06206278 — Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma · Phase 2 · terminated
NCT05145010 — Extension Study of Infigratinib in Children With Achondroplasia (ACH) · Phase 2 · enrolling by invitation
NCT05222165 — Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With · Phase 1, PHASE2 · withdrawn
NCT04504331 — Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced B · Phase 1 · terminated

Other recruiting trials for Cholangiocarcinoma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07291947 — PULSAR Combined With Immunotherapy and Chemotherapy · Phase 1, PHASE2 · recruiting
NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
NCT07263217 — Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury · NA · recruiting
NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05510427 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 15 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05510427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing